Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

AJMC

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

By Brigham Walker, PhD
Lalan Wilfong, MD

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 14th 2017

Patient Navigation in Immuno-Oncology

Shawn M. Regis, PhD

Patient navigation is immensely helpful in relieving some of the burden placed on cancer patients, and there are some particularly unique aspects of navigation as it pertains to immuno-oncology.

February 13th 2017

AJMCtv® Interviews, February 2017

Nicole Beagin Laura Joszt, MA

AJMCtvÂ® interviews let you catch up with experts in healthcare. Topics include challenges with immuno-oncology, including the patient voice in treatment decisions, and why payers should cover genomic testing.

February 13th 2017

Navigator Program Lowered Costs, Utilization for Elderly Cancer Patients

Christina Mattina

A program linking elderly cancer patients to lay navigators was shown to substantially reduce costs and decrease hospitalizations, making it an appealing tool for providing value-based oncology care.

February 13th 2017

Predicting Response to SCT in Patients With MDS

Surabhi Dangi-Garimella, PhD

A new study has identified key mutations that can direct the conditioning regimen prior to an allogenic hematopoietic stem cell transplant (SCT) in patients with myelodysplastic syndrome (MDS), leading to a better response.

Debra Madden Discusses Importance of Educating Patients on Immuno-Oncology Risks

February 13th 2017

Debra Madden Discusses Importance of Educating Patients on Immuno-Oncology Risks

Immuno-oncology is often portrayed as having less severe side effects than chemotherapy, but patients need to be aware that it does carry some risks, said Debra L. Madden, cancer research advocate and patient representative. Patients should not hesitate to report any adverse effects to their doctor.

February 12th 2017

MD Anderson Now an Oncology "Superhub" for Project ECHO

Surabhi Dangi-Garimella, PhD

MD Anderson Cancer Center, which first established its oncology-focused ECHO program in 2014 has now adopted a much bigger role, of a “superhub.”

Podcast: This Week in Managed Care - Drop in ACA Enrollment, and Other News

February 11th 2017

Podcast: This Week in Managed Care - Drop in ACA Enrollment, and Other News

Every week, The American Journal of Managed CareÂ® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This Week in Managed Care: February 10, 2017

February 10th 2017

This Week in Managed Care: February 10, 2017

This week, the top managed care stories included final enrollment numbers for the Affordable Care Act for 2017, a report that revealed low rates of lung cancer screening, and a study found that a population-based weight management strategies can prevent diabetes.

February 10th 2017

The Complex Relation Between Clinical Outcomes, Drug Approval, and Drug Price

Surabhi Dangi-Garimella, PhD

Does an FDA approval guarantee clinical benefit of a drug? How does it influence drug price?

February 9th 2017

Hopkins' Researchers Discover Carcinogenic Metals in E-Cigarette Liquid

Surabhi Dangi-Garimella, PhD

Analysis of the liquid used to make the aerosol in e-cigarettes has led to the discovery of high levels of 5 potentially toxic heavy metals.

February 8th 2017

Michigan Study Finds Obesity Lowers Hospice Use Among Seniors

Surabhi Dangi-Garimella, PhD

A long-term health study has found that seniors with a higher body mass index were less likely to make use of hospice care. Additionally, obese seniors spent significantly fewer days in hospice care than their nonobese counterparts.

February 8th 2017

Breast Cancer Patients Not Getting Desired Genetic Testing, Counseling

Christina Mattina

A recent JAMA study found that women with breast cancer would generally like to receive genetic testing and counseling, but less than one-third actually receive it.

February 7th 2017

PMC Report Proposes Strategies for Clinical Integration of Personalized Medicine

Surabhi Dangi-Garimella, PhD

The Health Care Working Group of the Personalized Medicine Coalition (PMC) has published a new report that provides a framework for the successful integration of personalized medicine in the clinic.

February 7th 2017

Low-Income Women Less Likely to Keep Jobs After Breast Cancer Treatment

Christina Mattina

Women with breast cancer are twice as likely to return to work after treatment if their employer makes accommodations for them, but workplace accommodation and job retention are significantly lower for low-income and minority women.

February 6th 2017

ACS Study Voices Concerns Over Low US Lung Cancer Screening Rates

Surabhi Dangi-Garimella, PhD

Lung cancer screening rates in the United States remained low and unchanged in 2015 despite recommendations that high-risk current and former smokers be screened.

David Fabrizio Explores Complexities of Surrogate Endpoints in Cancer Clinical Trials

February 6th 2017

David Fabrizio Explores Complexities of Surrogate Endpoints in Cancer Clinical Trials

The FDA has been willing to explore the utilization of surrogate endpoints like tumor response in clinical trials, but it is unclear whether these endpoints correlate with overall survival, said David Fabrizio of Foundation Medicine, Inc. However, he emphasized that overall survival does not necessarily benefit the patient if the additional days gained are not quality days.

Dr Stuart Goldberg Discusses How COTA Analyzes Oncology Data

February 6th 2017

Dr Stuart Goldberg Discusses How COTA Analyzes Oncology Data

Cancer Outcomes Tracking and Analytics (COTA) focuses on stratifying cancer patients by their many subtypes to understand the different treatments, outcomes, and costs for each, according to Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.

February 2nd 2017

Report Commissioned by COA Explores "Murky" World of Pharmacy DIR Fees

Christina Mattina

A white paper commissioned by the Community Oncology Alliance (COA) delved into the practice of “direct and indirect remuneration” fees administered by pharmacy benefit managers and how they could drive up drug prices for Medicare Part D beneficiaries and taxpayers.

February 1st 2017

Pembrolizumab Now Approved for First-Line Treatment of Lung Cancer in Europe and the US

Pembrolizumab (Keytruda) has received green light from the European Commission for the first-line treatment of a select population of adult patients with metastatic non-small cell lung cancer.

February 1st 2017

A Focus on Lifestyle and Appropriate Screening During National Cancer Prevention Month

Surabhi Dangi-Garimella, PhD

During the National Cancer Prevention Month, there will be renewed fervor among healthcare providers to ensure individuals pay greater attention toward preventive measures against cancer.

Dr David L. Porter Explains Variations in CAR-T Cell Trial Criteria

February 1st 2017

Dr David L. Porter Explains Variations in CAR-T Cell Trial Criteria

The criteria to enroll cancer patients in a clinical trial of CAR-T cells vary according to their disease, past therapy, and how far along they are in different treatments, said David L. Porter, MD, of the University of Pennsylvania Health System.

January 31st 2017

Study Recommends Measures to Fill Quality Gaps in Oncology Care

Surabhi Dangi-Garimella, PhD

A multicollaborative study has identified gaps in existing quality measures used by accountable care programs that could result in missed opportunities to improve patient outcomes.

Kim Eason on the Benefits of Patient-Centered Medical Homes

January 31st 2017

Kim Eason on the Benefits of Patient-Centered Medical Homes

Patient-centered medical homes are valuable because they allow insurers to look at the cost of all of the patient’s treatments, services, and physicians throughout the continuum of care, explained Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ.

January 30th 2017

Leaders of Cardiologists, Oncologists Decry Travel Ban

The American College of Cardiology is set to hold its annual meeting in the nation's capital March 17-20, 2017.

January 30th 2017

Need for Switch to Incretins in T2D an Indicator of Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

A retrospective analysis of evidence from prescription data gathered in Belgium and Italy has found that uncontrolled diabetes might be an early sign of pancreatic cancer.

January 29th 2017

Healthy People 2020 Targets Achieved in 30 States for Colorectal Cancer, 28 for Cervical Cancer

Surabhi Dangi-Garimella, PhD

A review of 2013 cancer statistics in the United States by the CDC showed that 67% of people survived at least 5 years after their cancer diagnosis.

Dr Joseph Alvarnas: Innovative Therapies Can Change Oncology Care Paradigm

January 29th 2017

Dr Joseph Alvarnas: Innovative Therapies Can Change Oncology Care Paradigm

Technological advances in cancer care have changed the very process of treatment, as now oncologists can gain more insight into the most effective therapy for each individual patient, according to Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology.

This Week in Managed Care: January 27, 2017

January 27th 2017

This Week in Managed Care: January 27, 2017

This week, the top managed care stories included Aetna and Humana's merger getting blocked, the first Affordable Care Act replacement proposal was unveiled, and an analysis of regional cancer death trends.

January 27th 2017

NICE Endorses Funding for Ibrutinib in Patients With CLL

Patients who have had at least 1 prior therapy or carry a 17p deletion or TP53 mutation are now eligible to be treated with ibrutinib (Imbruvica) in the United Kingdom.

Dr Carrie Stricker on Why Clinician Voices Are Needed in Health IT Development

January 27th 2017

Dr Carrie Stricker on Why Clinician Voices Are Needed in Health IT Development

The most transformative software companies are those that have seized the opportunity to incorporate clinician and patient voices into the design of their health IT tools, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

...

82 83 84 85 86 87 88 89 90

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions